Navigation Links
Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
Date:10/31/2012

rom the blood. Moreover, traditional LDL-lowering therapies such as statins actually stimulate the production of PCSK9, which limits their own ability to lower LDL-C.  Inhibiting the PCSK9 pathway is therefore a potentially novel mechanism for lowering LDL-C.

About SAR236553/REGN727 and the Phase 2 Program
SAR236553/REGN727, created using Regeneron's VelocImmune® technology, is a fully human monoclonal antibody directed against PCSK9, administered via subcutaneous injection.  By inhibiting PCSK9, a determinant of circulating LDL-C levels in the blood, SAR236553/REGN727 increases the number of free LDL receptors which can clear circulating LDL-C from the bloodstream.

SAR236553/REGN727 has been studied in three Phase 2 clinical studies: Two dose ranging studies in patients with hypercholesterolemia; one with 183-patients, and another with 92-patients, and one study of 77 patients with heterozygous familial hypercholesterolemia (heFH).  In the primary hypercholesterolemia trials treatment with different dose regimens of SAR236553/REGN727 on top of statin therapy significantly reduced LDL-C from baseline by 40% to 72% over the 8 or 12-week treatment period.  A third Phase 2 study was in patients with heFH whose LDL-C levels remained elevated despite statin therapy with or without ezetimibe.  Across the four tested doses of SAR236553/REGN727 administered for up to 12 weeks, patients achieved a mean reduction in LDL-C from baseline of 28% to 68%.  In the Phase 2 program, injection site reactions were the most common adverse events with SAR236553/REGN727.  Rare cases of hypersensitivity reaction were also reported.  There were five serious adverse events (SAE) in the active treatment arms (1.8%, 5/275) and two SAEs in the placebo groups (2.6%, 2/77).

About Regeneron Pharmaceuticals
Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sanofi Pasteur to add 2D barcode to six more vaccines
2. Sanofi US Launches Collaborate Activate Innovation Challenge
3. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
4. BioMed Realty Announces 80,500 Square Foot Lease Expansion For Regeneron Pharmaceuticals
5. Regeneron Named Worlds #1 Biopharmaceutical Employer in Science Magazine Annual Survey
6. Regeneron Announces September 2012 Investor Conference Presentations
7. Regeneron to Report Second Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on July 25, 2012
8. Regeneron Announces June 2012 Investor Conference Presentations
9. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
10. Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
11. BioMed Realty Announces 93,000 Square Foot Lease Expansion And Extension With Ironwood Pharmaceuticals At 301 Binney Street
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... -- Ascendant Solutions, Inc. (Pink Sheets: ASDS ) ... the fourth quarter and year ended December 31, 2014. ... less than $0.01 per share, on revenues of $8,018,000 ... with net income of $195,000, or $0.01 per share, ... 2013. The substantial increase in fourth quarter 2014 revenue ...
(Date:3/6/2015)... , March 6, 2015  AbbVie (NYSE: ... Health Care Conference on Thursday, March 12, 2015. ... will participate in a question and answer session at ... webcast of the presentation will be accessible through AbbVie,s ... archived edition of the session will be available later ...
(Date:3/6/2015)... , Alemania, 6 de marzo de 2015 /PRNewswire/ ... soluciones de gestión empresarial de imagen médica, fortalece ... el nombramiento de Randolph Sternberg como ... como director de operaciones. Logo ... Sternberg será responsable de las ventas y ...
Breaking Medicine Technology:Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 2Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 3Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 4Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 5TeraRecon fortalece su posición en EMEA 2TeraRecon fortalece su posición en EMEA 3
... 5, 2012 Cogmedix , ... device companies cost effectively improve their time-to-market, partnered ... the company,s refractive cataract surgery laser system. Designed ... critical manual steps in cataract surgery, the LensAR ...
... Officer of the American Telemedicine Association, has shared ... telehealth in the immediate future.  These trends represent ... challenges and opportunities for the industry.  ... 1. A Shift away from reimbursement models ...
Cached Medicine Technology:Cogmedix Provides High-Precision Subassembly for LensAR Revolutionary Refractive Laser 2ATA CEO: 7 Market Trends Shaping the Future of Telemedicine 2ATA CEO: 7 Market Trends Shaping the Future of Telemedicine 3
(Date:3/6/2015)... 06, 2015 “On Tap” takes the audience ... grand stage, to the silver screen and to modern day ... toe-tapping numbers and their famous eye-high kicks! Producers, directors and ... history of tap dancing in this robust show, showcasing one ... the United States. , “On Tap” is proud to ...
(Date:3/6/2015)... San Rafael, CA (PRWEB) March 06, 2015 ... the addition of three Maryland camps – two non-contact ... camps will be run by Perfect Performance Training, located ... camps will focus on developing position specific skills, speed ... will be hosted at Salisbury University with Marvin Graves, ...
(Date:3/6/2015)... At Natural Products Expo West, Makeena, ... of its powerful, location-aware iOS app that helps ... at any retailer that carries those products, including ... Booth 6054. , Makeena’s proprietary algorithm allows ... Paleo, and vegan, among many other product attributes. ...
(Date:3/6/2015)... Johnson & Johnson and Ethicon were hit with ... in Superior Court in the State of California in ... 12 awarded Mrs. Perry $700,000 in actual damages for ... TVT Abbrevo plastic sling for stress urinary incontinence. The ... $5 million in punitive damages. , According to court ...
(Date:3/6/2015)... First Choice Emergency Room opened ... is located at 13351 W. Bowles Avenue, Littleton, Colorado and ... ready 24-7 to provide the highest quality emergency medical care ... of First Choice Emergency Room Littleton. , First ... Metro Denver Chamber of Commerce and a medical community open ...
Breaking Medicine News(10 mins):Health News:The Legacy Dancers, a Dazzling Dance Troupe of Former Rockettes, Kick to New Heights in “On Tap: From Broadway to the Silver Screen” 2Health News:US Sports Camps to Host Three New Football Camps in Maryland 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 3Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:First Choice Emergency Room Opens New Facility in Littleton, Colorado 2
... inclination, study finds , WEDNESDAY, June 17 (HealthDay News) -- Bad ... violent street gangs. But a new study finds that the urge ... genes. , Boys who have a variant of the gene monoamine ... are not only more likely to be in gangs than boys ...
... , - SLA Centennial Observance ... Century , Elsevier has been awarded ... BioMedicine and the Life Sciences" at the Special Library,Association,s (SLA) ... published by Elsevier, many on behalf of renowned,societies, were also ...
... in Health and Life Sciences Category , , SUNNYVALE, ... Incorporated (Nasdaq: ARAY ), a global leader in ... the company,s president and CEO, received the Ernst & Young ... Life Sciences category in Northern California. According to Ernst ...
... has begun , , PITTSBURGH, June 17 Mylan ... subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. ... Drug Application (ANDA) for Temazepam Capsules USP, 22.5 mg. This ... and 30 mg strengths of the product. , , ...
... 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) ... agreement with Deerfield Management, a leading healthcare investment organization and ... funding through a credit facility. , , "We ... the potential of our business and that we have the ...
... the development of TMC207 and the discovery of new ... 17 A new landmark collaboration between the Global ... product development partnership, and Tibotec Inc., (Tibotec), a global ... Health Summit in response to the urgent need to ...
Cached Medicine News:Health News:Boys May Feel a Genetic Pull Toward Gangs 2Health News:Elsevier Honored as "The Most Influential Publisher of the Last 100 Years in BioMedicine and the Life Sciences" by the Special Libraries Association 2Health News:Elsevier Honored as "The Most Influential Publisher of the Last 100 Years in BioMedicine and the Life Sciences" by the Special Libraries Association 3Health News:Elsevier Honored as "The Most Influential Publisher of the Last 100 Years in BioMedicine and the Life Sciences" by the Special Libraries Association 4Health News:Accuray's Euan Thomson Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Recipient in Northern California 2Health News:Accuray's Euan Thomson Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Recipient in Northern California 3Health News:Arena Pharmaceuticals to Receive $100 Million from Deerfield Management 2Health News:Arena Pharmaceuticals to Receive $100 Million from Deerfield Management 3Health News:Arena Pharmaceuticals to Receive $100 Million from Deerfield Management 4Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 2Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 3Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 4Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 5Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 6
... Angiotensin Converting Enzyme (ACE), also known ... (EC 3.4.15.1) with a molecular weight of ... glycoprotein shows a single polypeptide chain, a ... is present in many different cell types ...
Vitamin B6 REA Vitamin Assays, Cardiovascular 001-RK-VB6...
Myoglobin RIA Lipid / Protein Quantification, Cardiovascular 024-IDC-11 Muscle Disease...
Anti-Gliadin IgA (Ab) EIA Gastrointestinal Markers 027-GD17 Celiac Disease Food Allergy...
Medicine Products: